SCHEMBL19956900

SCHEMBL19956900

CNc1c(NCCN2CCOCC2)c(=O)c1=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.49
KMT2A Q03164 4/20 0.49
MEN1 O00255 3/20 0.49
ALDH1A1 P00352 1/20 0.49
POLB P06746 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
MAPK1 P28482 1/20 0.48
GAA P10253 3/20 0.46
MAPT P10636 2/20 0.46
HSD17B10 Q99714 2/20 0.46
ALOX15 P16050 1/20 0.46
MALT1 Q9UDY8 1/20 0.45
PLK1 P53350 1/20 0.44
APAF1 O14727 1/20 0.44
NSD2 O96028 1/20 0.44
ACHE P22303 1/20 0.42
NPC1 O15118 2/20 0.42
LMNA P02545 2/20 0.42
RAB9A P51151 2/20 0.42
GLA P06280 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19956971 0.81 KDM4E (0.55) KDM4EKMT2AMEN1ALDH1A1POLB
SCHEMBL20927463 0.74 SMN1; SMN2 (0.45) KDM4EKMT2AMEN1ALDH1A1POLB
SCHEMBL39802 0.70 CARM1 (0.62) KDM4EALDH1A1SMN1; SMN2TDP1
SCHEMBL19409870 0.70 MALT1 (0.69) KDM4EKMT2AMEN1ALDH1A1POLB
SCHEMBL24485658 0.68 GRIN2D (0.41) KMT2AMEN1MAPTACHEHTT
SCHEMBL13887689 0.68 CARM1 (0.44) ALDH1A1POLBSMN1; SMN2MAPK1GAA
SCHEMBL19623614 0.68 MEN1 (0.52) KDM4EKMT2AMEN1ACHENPC1
SCHEMBL14454206 0.68 MEN1 (0.52) KDM4EKMT2AMEN1ALDH1A1MAPT
SCHEMBL18731410 0.67 CA12 (0.47) KDM4EALDH1A1SMN1; SMN2TDP1
SCHEMBL4401738 0.66 CA12 (0.53) KDM4EALDH1A1SMN1; SMN2GLAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same Guangdong Raynovent Biotech Co., Ltd. (CN) 2020-05-19 US disclosed
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Guangdong Raynovent Biotech Co., Ltd. (CN) 2019-04-25 US disclosed
EP-3293177-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2018-03-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME ABL1, LCK, ERBB2 KDM4E 843/4885KMT2A 1030/4885MEN1 1450/4885
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same ABL1, LCK, ERBB2 KDM4E 843/4885KMT2A 1030/4885MEN1 1450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.